Can Alpha Lipoic Acid Help Type 2 Diabetes Treatment?

Alpha-lipoic acid (thioctic acid or ALA) is an antioxidant that is produced naturally by your body. Blood sugars and insulin sensitivity have also been shown to improve with ALA treatment. ALA is used for diabetes and nerve-related symptoms of diabetes including burning, pain, and numbness in the legs and arms. ALA are approved in Germany for the therapy of these symptoms.

Alpha Lipoic Acid Diabetes Benefits

In several studies, ALA appears to help lower blood sugar levels. A review of literature reported in Endocrine, Metabolic and Immune Disorders Drug Targets in 2009 demonstrated that ALA was an efficacious medicinal agent. Supplement of 300 mg of alpha-lipoic acid a day for 4 weeks improved vascular health by 44 % in diabetics, compared to a placebo. A study reported in the autumn 2006 edition of  Hormones demonstrated  that insulin sensitivity improved in type 2 diabetic patients who took 600 mg of ALA twice daily for 4 weeks.

In a study of 20 patients with type 2 diabetes mellitus, intravenous infusion of 500 mg/day of alpha lipoic acid for 10 days also improved insulin sensitivity when measured 24 hours after the last infusion. A clinical trial in 13 people with type 2 diabetes mellitus found that a single intravenous infusion of 1000 mg of alpha-lipoic acid improved insulin-stimulated insulin sensitivity by 50% compared to a placebo infusion. In a study of a controlled-release form of oral alpha lipoic acid, 15 patients with type 2 diabetes mellitus took 900 mg/day for 6 weeks and 1,200 mg/day for another 6 weeks, in addition to their current drugs. At the end of 12 weeks, plasma fructosamine concentrations decreased by approximately 10% from baseline.

Seventy-four patients were divided into four groups (600 mg Lipoic acid once, twice, or thrice daily and placebo) for a four-week study to investigate its effects on insulin sensitivity, using a measurement called the MCR (Metabolic Clearance of Glucose). Alpha-lipoic acid therapy led to important improvement in MCR, though there was no significant difference between doses. A meta-analysis of clinical studies of ALA in diabetic patients demonstrated a important reduction in neuropathic symptoms. Diabetes patients are  prone to kidney disease due to oxidative stress. A German study demonstrated that diabetic patients with kidney disease who were with ALA had a slower progression in their illness than non-treated people over a period of 18 months.

Carnosine and its Possible Roles in Cataract

Carnosine occurs naturally in the body’s muscle and nervous tissues and is formed by the amino acids alanine and histidine. It is found in relatively high amounts in several body tissues in skeletal muscle, heart muscle, and brain. In recent years Russian researcher have been researching an analogue of the di-peptide carnosine called NAC (n-acetylcarnosine) which they claim to be effective in the therapy of cataract.

N-acetylcarnosine and Cataracts

L-carnosine  protects proteins in the eye from harm caused by MDA (malondialdehyde) and stops malondialdehyde from inducing cross-linking. Carnosine is efficacious at treating senile cataracts, and at slowing down cataract development. The glycation process can change lens proteins and significantly contribute to diabetic cataract formation and retinopathy. New researches suggests that the most substantial action of carnosine is its anti-glycation impact. Glycation can be called as the binding of a protein molecule to a glucose molecule resulting in the formation of damaged, nonfunctioning structures. Glycation alters protein structure and reduces biological activity. Glycated proteins, which accumulate in affected tissue. Several  age-related ailments such as cataract, are  partially attributable to glycation.

eyeCarnosine containing eyedrops have showed effectiveness in treating a different of ophthalmic problems, including corneal diseases, increased intraocular pressure, glaucoma and cataracts, and impaired vision from any cause. Explained that researches out of  Italy and Russia has shown that, l-carnosine, may be all that’s needed to dissolve cataracts, improve vision, and prevent redundant surgery. A new treatment for cataracts is NAC (N-acetylcarnosine). NAC has a highly statistical and very important clinical success rate for patients within 3-12 months of therapy. This therapy was improved by opthalmologist Dr. Babizhayev in Moscow. Many of the researches demonstrating the effectiveness of carnosine in preventing or treating cataracts in humans has been done by Dr. Babizhayev. Application of a 1 percent solution of N-acetylcarnosine to the eyes has dissolved cataracts. This works by preventing and reversing cross linking of the lens proteins that produces opacification and impaired vision. In 6 months, 90 percent of participants had developed vision. In 1994, scientists from the “Moscow Helmholtz Research Institute of  Eye Diseases” linked the antioxidant effects of this compound to the possible for prevention or partially reversing cataract development.

A canine study using 1.0% NAC in its patented formulation used 30 dogs in the treatment group, 15 dogs in placebo-controlled group, and 10 dogs without therapy. After six months of therapy, 96% of eyes in the treatment group demonstrated healing in the slit image and retroillumination photographs. In 2009 a trial of 75 patients with cataracts and 72 without, 1.0% NAC was instilled daily for nine months. In both groups visual acuity and reduction in glare sensitivity reached statistical significance at nine months. Researchers in China explained that carnosine-containing eyedrops used to treat 96 cataract patients over 60 years of age resulted in 100 % healing in primary senile cataract, and 80 % in those with mature senile cataract. A Russian trial was designed to document and quantify the changes in lens clarity over a 6 to 24 month period for 49 participants. Participants average age was 65 and all suffered from senile cataract of a minimal to advanced opacification. The subjects received either a 1% solution of NAC eye-drops or a placebo, as 2-drops twice a day into each eye. At six months, 88 % of all eyes treated with NAC had an amelioration of glare sensitivity. 41 % of all eyes treated with NAC had a important amelioration of the transmissivity of the lens, and 90% of the eyes treated with NAC demonstrated an healing in visual acuity.

Coenzyme Q10 Could Help Reduce Heart Deaths

Ubiquinol is the reduced form of Coenzyme Q10. Researches have shown that Ubiquinol is useful to the cardiovascular system, helps support arterial health, and promotes optimial heart health. Ideal blood levels for those afflicted with congestive heart failure are considered to be greater than 3.5 micrograms per milliliter. A clinical trial demonstrated that supplementation with only 150 mg per day (within 28 days) of ubiquinol resulted in CoQ10 blood levels of 3.84 mcg/mL. In study participants who took 300 mg per day of ubiquinol, blood CoQ10 levels reached 7.28 mcg/mL.

Coenzyme Q10 and Heart Diseases

CHF (congestive heart failure) means the heart cannot pump enough blood to keep up with the body’s needs. The most common variety of  Congestive heart failure, involves weakening of the muscle in the heart’s left ventricle following bouts of ischemia and/or infarction. Coenzyme Q10 levels are decreased in the heart muscle of individuals with heart failure, with the deficiency becoming more pronounced as heart failure severity worsens. Being at the core of cellular energy processes it assumes significance in cells with high energy requirements like the cardiac cells which are extremely sensitive to Coenzyme Q10 de?ciency produced by cardiac diseases. Coenzyme Q10 has therefore, a potential role for prevention and therapy of heart ailments by improving cellular bioenergetics.

When started within 72 hours of myocardial infarction and taken for one year, CoQ10 appears to significantly lower the risk of heart-related events including non-fatal myocardialinfarction. Ubiquinol were associated with improvements in the capability of the heart to pump blood, as well as general heart health scores, according to results reported in the “American Journal of Clinical Nutrition“. In people with chronic heart failure 300 mg of  Coenzyme Q10 per day was able to strengthen the heart over a four week period, as did exercise. Coenzyme Q10 levels in the blood were elevated 4 times higher from the supplements, compared to the control group, and even higher when Coenzyme Q10 was combined with exercise. The ejection fraction is an substantial measurement in determining how well your heart is pumping out blood and in diagnosing and tracking heart failure. Healthy individuals have an ejection fraction of 50-75%, while those with CHF (congestive heart failure) usually have values below 20-30%. In a study performed by Dr. Peter Langsjoen, the ejection fraction improved from 24% up to 45% in ubiquinol-treated patients who had follow-up echocardiograms.

In a clinical study of patients with congestive heart failure were given 580 mg per day of ubiquinone. These individuals found increases in blood levels of  CoQ10 levels, along with important developments in the ejection fraction of the heart and improvement of the left ventricle, the part of the heart that sends blood out to the body. In other, randomized placebo controlled, double-blind study, 641 people with more severe congestive heart failure were given either a placebo or 150 mg/day of  Coenzyme Q10 for one year. The number of patients requiring hospitalization because of worsening failure was 38 percent less in the Coenzyme Q10 group. Coenzyme Q10 cuts mortality by half in people with heart failure, scientists from Denmark reported at the annual meeting of the Heart Failure Association of the European Society of Cardiology, which took place in Lisbon. Coenzyme Q10 is the first drug to improve survival in chronic heart failure since ACE inhibitors and beta blockers more than a decade ago and should be added to standard heart failure treatment, according to lead author Professor Svend Aage Mortensen.

Statins Reduce the Synthesis of Coenzyme Q10

Ubiquinol may be important for patients taking cholesterol-lowering statin medications because statin medications can reduce Coenzyme Q10 levels in the body. It has a protective property on red blood cells, helping especially to maintain levels during long-term therapy with statins.

Statin Drugs and CoQ10 Deficiency

Naturally produced in bodies, ubiquinol is an active form of  CoQ10 (Coenzyme Q10), which has been shown to have quite strong antioxidant property. As an antioxidant, Coenzyme Q10 helps protect proteins and mitochondrial DNA from oxidative damage and, supports healthy heart. The level of CoQ10 in tissues decreases as people get older. Some data state that this decline in Coenzyme Q10 begins around age 20, and noticeable declines in Coenzyme Q10 in the heart and other organs becomes apparent after the age of 40. In 1977 the “Journal of  Orthomolecular Medicine” reported that a 77 year old person has 57 % less Coenzyme Q10 than a 20 year old. An analysis of heart muscle tissue collected from people with heart disease showed a marked decrease in the tissue Coenzyme Q10 concentration. It has been shown that patients with lower ubiquinol concentrations and decreases in ATP production in the heart muscle tissue suffered more serious types of heart disease than individuals with higher levels of Coenzyme Q10.

HMA Co-A reductase inhibitors or statin drugs inhibit one of the important steps in CoQ10 synthesis. These medications have been associated with a diminution in serum and muscle tissue coenzyme Coenzyme Q10 levels and may play a role in statin-induced myopathy. Statin treatment reduces blood Coenzyme Q10 concentrations. Statin-induced Coenzyme Q10 depletion is well documented in animal and human studies with deleterious cardiac consequences in both animal models and human studies. Because of this close correlation, co-administration of CoQ10 along with statins is recommended by some doctors to prevent or treat the adverse effects of statin drugs.

A Columbia University study found that 30 days of statin treatment (80 mg/day) decreased Coenzyme Q10 levels by half. In 2004, a study reported in the “American Journal of  Cardiology” documented evidence of early heart muscle weakness in 70% of patients taking statin medication treatment for a period of 6 months. Ubiquinol may help limit muscle pain from taking statins and help avoid rhabdomyolysis. A double-blind study found CoQ10 can decrease muscle pain associated with statin medication use. Participants were given 100 mg Coenzyme Q10 for 30 days finding pain severity decreased by 40 percent, and pain interference with daily activities decreased by 38 percent in the Coenzyme Q10 group.

What Is Serrapeptase Taken For?

Serrapeptase is a protein enzyme isolated from the non-pathogenic enterobacteria Serratia E15 found in silkworms. Once the silkworm has completed its transformation into a moth, it uses this substance to “melt” a hole in its cocoon, thus that it can escape. This enzyme is absorbed through the intestines and transported directly into the bloodstream.

Serrapeptase Benefits and Medical Researches

Serrapeptase enzyme, particularly in Asia and Europe it is clinically used for anti-inflammatory problems such as arthritis, atherosclerosis, fibrocystic breast disease and carpal tunnel syndrome.

Serratiopeptidase is able to dissolve the fibrin and other dead or damaged tissue without harming living tissue. This could enable the dissolution of atherosclerotic plaques without causing any harm to the inside of the arteries. Hans Nieper, German doctor, has reported important improvements from serrapeptase therapy in the circulation of a number of patients with previously compressed arteries. Especially, advises the use of this enzyme to treat blocked carotid arteries when classic surgery is too risky. Because the enzyme digests non-living tissue and leaves live tissue alone, it may be efficacious in removing the deposits of fatty substances, cellular waste products, cholesterol, calcium and fibrin on the inside of the arteries. The fibrinolytic activity of serrapeptase may also be able to help with thickened blood, increased risk of stroke, and phlebitis.

MedicineIn his researches, Dr. Nieper proved that serratiopeptidase was capability of dissolving and digesting the substances that cause plaque formation on the arterial walls, such as cholesterol, calcium, cellular wastes, various fats, and fibrin, a clotting agent. Excessive plaque results in partial or complete blockage of blood flow through an artery, resulting in arteriosclerosis  which could cause a heart attack or stroke. Dr. Nieper explained that serratiopeptidase digests non-living tissue, blood clots, cysts, arterial plaque and inflammation in all forms. It protects against strokes and has been found to be more effectual and fast than EDTA chelation therapies in removing arterial plaque. Serrapeptase acts to safely and effectively reverse chronic inflammation. In recent years, a growing number of sresearchers have come to realize that one of the primary causes for the deposits of deleterious, plaque-forming substances inside arterial walls is chronic, low-grade inflammation.

Serratiopeptidase is a strong therapy for pain and inflammation. Various researches confirm its anti-inflammatory effects, and it has been used for this reason in the reduction of chronic sinusitis and other chronic or acute inflammatory conditions. Serratiopeptidase anti-inflammatory effects are similar to those of the ibuprofen, salicylates and non-steroidal anti-inflammatories. Unlike NSAID pain drugs, serrapeptase does not cause risky internal bleeding nor is it addictive like other pain drugs. In a study 2008; compared serrapeptase and its anti-inflammatory effect with aspirin and two human pancreatic proteolytic enzymes (chymotrypsin and trypsin). Though all groups were effective at reducing inflammation, serrapeptase  was the most effective.

In various studies serratiopeptidase has significantly reduced the elasticity and viscosity of nasal mucus offering great help to people with chronic sinus problems. Serrapeptase reduces the thickness and viscosity of the mucus and improves the elimination of it through bronchopulmonary secretions. Patients treated with serrapeptase for sinusitis and laryngitis experienced a significant decreased in severity of pain, rapid improvement of symptoms after 3-4 days, as well as decreased in nasal stuffiness, infected secretions, and fever. In a study conducted in Italy, gave serratiopeptidase to 193 participants suffering from acute or chronic ear, nose or throat problems over a period of 3 to 4 days. The scientists rated therapy as excellent or good for 97% of participants taking serratiopeptidase compared with just 21% in the placebo group. A study in Japan investigated the efficacy of serratiopeptidase on sputum properties and symptoms in individuals with chronic airway diseases. After four weeks of serratiopeptidase therapy, sputum output, viscosity and sputum neutrophil count decreased significantly. A study reported in the March 2008 edition of  Journal of  Oral and Maxillofacial Surgery demonstrated that Serratiopeptidase supplement reduced pain and inflammation following dental surgery.

Carpal Tunnel Syndrome (CTS) is an inflammatory disease of the hand and wrist that is characterized by intense, longlasting pain, inflammation and disability. CTS is usually the result of a combination of factors that increase pressure on the median nerve and tendons in the carpal tunnel, rather than a problem with the nerve itself. Symptoms mostly start gradually, with frequent burning, tingling, or itching numbness in the palm of the hand and the fingers, particularly the thumb and the index and middle fingers. Scientists in India conducted a study to assess the response of serratiopeptidase in people with carpal tunnel syndrome. 20 patients with carpal tunnel syndrome were evaluated clinically after six weeks taking serratiopeptidase. 65 % demonstrated significant clinical development, which was supported by improvement in electrophysiological parameters. While surgery had been considered the first  therapy,  new researches  reveal that the use of serratiopeptidase in conjunction with bromelain and Vitamins B2 and B6 is also useful.

Serratiopeptidase has proven invaluable in accelerating the healing process for leg ulcers, torn ligaments, sprained muscles, and other traumatic injuries, edema as well as post-operative inflammation. A study was conducted on the effect of serratiopeptidase on post-operative pain of the ankle and swelling. In the serratiopeptidase group, the swelling decreased by 50 percent on the third post-operative day, while in the control groups no reduction in swelling occurred. Another double-blind study, reported in the “Pharmatherapeutica“, found that serratiopeptidase reduced swelling in patients who underwent surgery to treat empyema. A cyst or a benign fibrocystic lump that moves freely within the breast tissue characterizes fibrocystic breast disease, a condition that affects millions of women. In a double-blind study, serratiopeptidase was found to decrease breast pain, breast swelling and induration in 85.7 percent of the patients taking the supplement. Experts concluded that serratiopeptidase is a influential and safe remedy for the therapy of breast engorgement.

Serrapeptase Dosage

The enzyme activity is measured in units and are based on the ratio of 10 mg of serratiopeptidase equaling 20,000 units of activity. According to Dr. Nieper, just 3 three 5 mg tablets of serrapeptase daily for twelve to eighteen months are sufficient to remove fibrous blockages from constricted coronary arteries, as confirmed in many of his patients by ultrasound examination. For pain, start with 10 mg daily and work up to 20 mg if necessary. Serrapeptase capsules and tablets  are enteric coated and are taken on an empty stomach to ensure that they are activated in the small intestine, rather than in the stomach. Non-enteric coated capsules or tablets  are rapidly destroyed by the stomach acid.